Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2014 1
2015 1
2017 1
2018 2
2019 2
2020 5
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Citations

2 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC).
Rafii H, Frère C, Benzidia I, Crichi B, Andre T, Assenat E, Bournet B, Carpentier A, Connault J, Doucet L, Durant C, Emmerich J, Gris JC, Hij A, Le Hello C, Madelaine I, Messas E, Ndour A, Villiers S, Marjanovic Z, Ait Abdallah N, Yannoutsos A, Farge D. Rafii H, et al. J Med Vasc. 2020 Feb;45(1):28-40. doi: 10.1016/j.jdmv.2019.12.004. Epub 2020 Jan 8. J Med Vasc. 2020. PMID: 32057323 Review.
Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer progression. ...The guidelines underscore the gravity of developing VTE in cancer and recommend the best approaches for treating and pr …
Venous thromboembolism (VTE) is a common disease complication in cancer patients and the second cause of death after cancer pr …
Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC).
Farge D, Cajfinger F, Falvo N, Berremili T, Couturaud F, Bensaoula O, Védrine L, Bensalha H, Bonnet I, Péré-Vergé D, Coudurier M, Li V, Rafii H, Benzidia I, Connors JM, Resche-Rigon M. Farge D, et al. Oncotarget. 2018 Jun 5;9(43):26990-26999. doi: 10.18632/oncotarget.25454. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930745 Free PMC article.
BACKGROUND: Clinical guidelines recommend at least 3-months low molecular weight heparin (LMWH) treatment for established venous thromboembolism (VTE) in cancer patients. However, no study has analyzed the impact of 3-6 months of LMWH therapy on quality-of-life (QoL) in …
BACKGROUND: Clinical guidelines recommend at least 3-months low molecular weight heparin (LMWH) treatment for established venous thromboembo …
Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies.
Frere C, Lejeune M, Kubicek P, Faille D, Marjanovic Z; Groupe Francophone Thrombose et Cancer. Frere C, et al. Cancers (Basel). 2019 Oct 24;11(11):1639. doi: 10.3390/cancers11111639. Cancers (Basel). 2019. PMID: 31653027 Free PMC article. Review.
In contrast, data on the chemoprotective effect of aspirin against other cancers are less clear and remain controversial. Most data come from secondary analyses of cardiovascular prevention trials, with only a limited number reporting cancer outcomes as a prespecifi …
In contrast, data on the chemoprotective effect of aspirin against other cancers are less clear and remain controversial. Most data c …
[Venous thromboembolism and pancreatic cancer].
Frère C, Bournet B, Benzidia I, Jamelot M, Debourdeau P, Hij A, Rafii-Elayoubi H, Buscail L, Farge D; Groupe francophone thrombose et cancer. Frère C, et al. J Med Vasc. 2018 Jul;43(4):246-254. doi: 10.1016/j.jdmv.2018.05.003. Epub 2018 May 24. J Med Vasc. 2018. PMID: 29981733 Review. French.
Pancreatic cancer (PC) is a devastating malignancy with an overall 5-year survival of 8% for all stages combined. ...The disease course is often complicated by venous thromboembolism (VTE) events, which per se account for significant morbidity and mortality, with significa …
Pancreatic cancer (PC) is a devastating malignancy with an overall 5-year survival of 8% for all stages combined. ...The disease cour …
Patient education program at the forefront of cancer-associated thrombosis care.
Sebuhyan M, Crichi B, Deville L, Le Maignan C, Bonnet C, Marjanovic Z, Rueda J, Bensaoula O, Ndour A, Frere C, Madeleine I, Farge D. Sebuhyan M, et al. J Med Vasc. 2021 Oct-Dec;46(5-6):215-223. doi: 10.1016/j.jdmv.2021.08.001. Epub 2021 Aug 24. J Med Vasc. 2021. PMID: 34862015
INTRODUCTION: Treatment of cancer-associated thrombosis (CAT) requires specific approaches, although it is well codified in most cases. ...The Groupe francophone et cancer (GFTC) members aim at facilitating access to CAT-PEP for both pati …
INTRODUCTION: Treatment of cancer-associated thrombosis (CAT) requires specific approaches, although it is well codified in mo …
Long-term use of tinzaparin for the treatment of cancer-associated thrombosis in clinical practice: Insights from the prospective TROPIQUE study.
Frere C, Crichi B, Rueda-Camino JA, Cajfinger F, Spiess N, Janus N, Le Maignan C, Marjanovic Z, Farge D. Frere C, et al. J Med Vasc. 2022 Apr;47(2):56-64. doi: 10.1016/j.jdmv.2022.04.004. Epub 2022 May 20. J Med Vasc. 2022. PMID: 35691664
BACKGROUND: Real word data on the efficacy and safety of long-term use of tinzaparin for the treatment of cancer-associated thrombosis (CAT) are scarce. METHODS: We performed a post-hoc analysis of all cancer patients included in the prospective multicenter o …
BACKGROUND: Real word data on the efficacy and safety of long-term use of tinzaparin for the treatment of cancer-associated thromb …
Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients.
Farge D, Durant C, Villiers S, Long A, Mahr A, Marty M, Debourdeau P; Groupe Francophone Thrombose et Cancer (GFTC). Farge D, et al. Thromb Res. 2010 Apr;125 Suppl 2:S108-16. doi: 10.1016/S0049-3848(10)70027-X. Thromb Res. 2010. PMID: 20433988 Review.
Increased prevalence of Venous thromboembolism (VTE), as defined by deep-vein thrombosis (DVT), central venous catheter (CVC) related thrombosis or pulmonary embolism (PE) in cancer patients has become a major therapeutic issue. ...Thrombosis is the se …
Increased prevalence of Venous thromboembolism (VTE), as defined by deep-vein thrombosis (DVT), central venous catheter (CVC) related …
[New international guidelines for curative treatment and prophylaxis for venous thromboembolism (VTE) in cancer patients and the dedicated smartphone application].
Benzidia I, Connault J, Solanilla A, Michon-Pasturel U, Jamelot M, Nguessan MK, Hij A, Le Maignan C, Farge D, Frère C; pour le Groupe Francophone Thrombose et Cancer. Benzidia I, et al. J Med Vasc. 2017 Dec;42(6):375-383. doi: 10.1016/j.jdmv.2017.09.006. Epub 2017 Nov 15. J Med Vasc. 2017. PMID: 29203044 Review. French.
Cancer patients are also more likely to present recurrent VTE and major bleeding while taking anticoagulants. Management of VTE in these patients is always challenging and remains suboptimal worldwide. In 2013, the International Initiative on Thrombosis and Cance …
Cancer patients are also more likely to present recurrent VTE and major bleeding while taking anticoagulants. Management of VTE in th …
Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study.
Sevestre MA, Belizna C, Durant C, Bosson JL, Vedrine L, Cajfinger F, Debourdeau P, Farge D; Carmen Investigators for the Groupe Francophone Thrombose et Cancer (GFTC). Sevestre MA, et al. J Mal Vasc. 2014 May;39(3):161-8. doi: 10.1016/j.jmv.2014.03.001. Epub 2014 Apr 18. J Mal Vasc. 2014. PMID: 24746736
Cancer is associated with venous thromboembolism in 20% of patients. ...Good clinical practice was defined as initial 10-day treatment with injectable molecules followed by long-term treatment with low molecular weight heparin for at least 3 months. Demographic data, ca …
Cancer is associated with venous thromboembolism in 20% of patients. ...Good clinical practice was defined as initial 10-day treatmen …
15 results